NY-WUNDERKIND
6.3.2023 06:02:36 CET | Business Wire | Press release
Wunderkind, the leading performance marketing solution that delivers guaranteed revenue and performance for brands, publishers and advertisers, announced the appointment of Bill Ingram, a proven marketing technology leader, as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005559/en/
Former Adobe and Cheetah Digital executive Bill Ingram named CEO of leading performance marketing solution Wunderkind. (Photo: Business Wire)
Ingram brings over 30 years of experience scaling tech start-ups, leading enterprise SaaS organization advancement, and driving product development and growth. Before joining Wunderkind, Ingram served as President and Chief Product Officer at Cheetah Digital, driving the global innovation and advancement of next generation B2C marketing automation solutions. Previously, Ingram was Vice President and General Manager at Adobe, overseeing the organization’s Analytics Cloud worldwide business for over 10 years. Ingram previously held leadership roles with several SaaS organizations, including Sybase and Omniture, which was acquired by Adobe for $1.8B.
In his role as CEO, Ingram will establish and drive Wunderkind’s strategic direction and product expansion in support of increasing customer engagement for the world’s leading brands. He will focus on taking Wunderkind’s products and services to new levels, while maintaining an industry leading revenue guarantee. Additionally, he will work to advance Wunderkind’s product suite for leading publishers to further engage consumers in an impactful, non-intrusive way that fosters increased brand visibility and qualified engagement. Ingram will lead the team towards ensuring Wunderkind’s solutions continue to help advertisers reach their priority audiences while delivering a quality user experience across a network of premium publishers. Furthermore, he will concentrate on leading the Wunderkind team to eclipsing its over 34% year-over-year revenue increase realized last year.
“Wunderkind has achieved exponential growth by delivering undeniable marketing performance and increased revenue for the world’s most renowned eCommerce brands, who are constantly competing to attract, retain and convert valued customers,” said CEO Bill Ingram. “Wunderkind has proven that channels once perceived as top- and middle-of-funnel can be transformed into significant revenue drivers. I look forward to leading the company’s all-star team as we embark upon a new chapter of strategic innovation and proliferation.”
Ingram’s appointment comes as Wunderkind is poised for continued acceleration in 2023 on the heels of major milestones in 2022, which included: a $76M in Series C financing led by Neuberger Berman; 34% year-over-year revenue gain; and the opening of offices in Australia, Canada, and the Netherlands to further its global reach.
“In a fiercely competitive eCommerce landscape, marketers are under tremendous pressure to deliver verifiable ROI for every dollar spent. Wunderkind's pioneering solutions stand superior to all other solutions in our industry, assisting countless brands in driving provable revenue while building lasting customer loyalty,” said Stephen Collins, Wunderkind’s Board Chairman. “We are confident that Bill’s proven leadership, industry expertise, and success in scaling global technology organizations will realize a new era of growth and success for Wunderkind’s customers, partners and employees alike.”
During the 2022 holiday season, despite a challenging macroeconomic climate, Wunderkind was pivotal in helping its clients achieve more than $1B in directly attributable revenue. The company recently added a host of premium publishers and global retailers to its client roster, including; Rag & Bone, Refinery29, JLo Beauty, Uniqlo, e.l.f. cosmetics, Swatch, Outdoor Voices, See's Candy.
About Wunderkind
Wunderkind is a leading performance marketing solution that drives guaranteed revenue for brands, publishers, and advertisers. As first-party data becomes central to efficient growth, Wunderkind enables brands to identify their website visitors on an individual level and deliver more of their highest-performing, one-to-one messages through websites, emails, texts, and ads than otherwise possible. Wunderkind drives $5 billion annually in directly attributable revenue for brands like Uniqlo, Refinery29, Sonos, and HelloFresh, often ranking as a top three performance channel in their own analytics platforms. Discover how Wunderkind can drive efficient growth for your brand by visiting wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom